Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Thoracic 1Sarcoma 1Breast 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 41Cisplatin 40Paclitaxel 35Radiotherapy 32Docetaxel 19Pemetrexed 18Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 10Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Pharmacogenomic Testing × Thoracic × Clear all
NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
102 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡